Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 ObsEvaLantern PharmaOvid TherapeuticsAssembly BiosciencesLotus Pharmaceuticals
SymbolNASDAQ:OBSVNASDAQ:LTRNNASDAQ:OVIDNASDAQ:ASMBOTCMKTS:LTUS
Price Information
Current Price$3.04$17.11$3.69$4.36$0.05
52 Week RangeHoldHoldBuyBuyN/A
MarketRank™
Overall Score1.41.21.51.60.0
Analysis Score3.23.03.33.30.0
Community Score2.33.02.82.30.0
Dividend Score0.00.00.00.00.0
Ownership Score0.80.00.81.70.0
Earnings & Valuation Score0.60.00.60.60.0
Analyst Ratings
Consensus RecommendationHoldHoldBuyBuyN/A
Consensus Price Target$11.80$24.50$11.63$11.50N/A
% Upside from Price Target288.16% upside43.19% upside215.04% upside163.76% upsideN/A
Trade Information
Market Cap$174.96 million$191.12 million$242.63 million$166.75 million$146.93 million
Beta0.99N/A1.860.611.29
Average Volume5,815,825219,7143,920,8491,275,117169,555
Sales & Book Value
Annual RevenueN/AN/AN/A$15.96 millionN/A
Price / SalesN/AN/AN/A10.45N/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.01 per shareN/A$1.46 per share$10.49 per shareN/A
Price / BookN/AN/AN/A0.42N/A
Profitability
Net Income$-108,790,000.00N/A$-60,460,000.00$-97,630,000.00N/A
EPS($2.49)N/A($1.54)($3.72)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/AN/AN/A∞
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-60.14%N/A
Return on Equity (ROE)-256.23%N/A-140.96%-18.75%N/A
Return on Assets (ROA)-93.21%N/A-108.72%-15.89%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.14%0.01%N/AN/AN/A
Current Ratio2.06%27.58%5.03%14.66%N/A
Quick Ratio2.06%27.58%5.03%14.66%N/A
Ownership Information
Institutional Ownership Percentage52.74%2.58%39.59%92.23%N/A
Insider Ownership PercentageN/AN/A29.80%7.10%N/A
Miscellaneous
Employees53465139233
Shares Outstanding57.55 million11.17 million65.75 million38.25 million2.94 billion
Next Earnings Date5/4/2021 (Estimated)6/9/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableNot OptionableOptionableNot Optionable
SourceHeadline
Short Interest in Lotus Pharmaceuticals, Inc. (OTCMKTS:LTUS) Decreases By 67.0%Short Interest in Lotus Pharmaceuticals, Inc. (OTCMKTS:LTUS) Decreases By 67.0%
americanbankingnews.com - March 27 at 4:28 AM
Lotus Pharmaceuticals, Inc. Current with OTC MARKETSLotus Pharmaceuticals, Inc. Current with OTC MARKETS
markets.businessinsider.com - March 17 at 8:24 AM
DateCompanyBrokerageAction
1/12/2021ObsEvaWedbushReiterated Rating
1/12/2021ObsEvaSVB LeerinkBoost Price Target
1/4/2021ObsEvaHC WainwrightLower Price Target
11/9/2020ObsEvaJPMorgan Chase & Co.Downgrade
7/6/2020ObsEvaBMO Capital MarketsDowngrade
12/10/2019ObsEvaRoyal Bank of CanadaBoost Price Target
11/8/2019ObsEvaCredit Suisse GroupDowngrade
8/18/2020Lantern PharmaThinkEquityReiterated Rating
8/18/2020Lantern PharmaColliers SecuritiesReiterated Rating
3/4/2021Ovid TherapeuticsUBS GroupBoost Price Target
12/2/2020Ovid TherapeuticsCantor FitzgeraldReiterated Rating
12/2/2020Ovid TherapeuticsSmith Barney CitigroupDowngrade
12/2/2020Ovid TherapeuticsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
12/2/2020Ovid TherapeuticsLADENBURG THALM/SH SHLower Price Target
12/2/2020Ovid TherapeuticsJMP SecuritiesDowngrade
10/2/2020Ovid TherapeuticsWilliam BlairReiterated Rating
6/18/2020Ovid TherapeuticsPiper SandlerReiterated Rating
3/2/2021Assembly BiosciencesTruistLower Price Target
2/28/2021Assembly BiosciencesRobert W. BairdReiterated Rating
2/25/2021Assembly BiosciencesMizuhoReiterated Rating
11/6/2020Assembly BiosciencesJefferies Financial GroupDowngrade
9/19/2019Assembly BiosciencesChardan CapitalReiterated Rating
(Data available from 4/10/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
Comparison Ideas:

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.